Active Not Recruiting PHASE3 INTERVENTIONAL 3-arm NCT02445391

Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy

A Randomized Phase III Post-operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy

Sponsor: ECOG-ACRIN Cancer Research Group

Conditions Estrogen Receptor Negative HER2/Neu Negative Invasive Breast Carcinoma Progesterone Receptor Negative Stage II Breast Cancer Stage IIA Breast Cancer Stage IIB Breast Cancer Stage III Breast Cancer Stage IIIA Breast Cancer Stage IIIB Breast Cancer Stage IIIC Breast Cancer Triple-Negative Breast Carcinoma

Interventions Capecitabine Carboplatin Cisplatin

Updated 19 times since 2017 Last updated: Feb 27, 2026 Started: Oct 20, 2015 Primary completion: Apr 7, 2021 Completion: Mar 29, 2031

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Estrogen Receptor Negative and HER2/Neu Negative, this trial is ongoing. The trial is conducted by ECOG-ACRIN Cancer Research Group and has accumulated 19 data snapshots since 2015. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

19 versions recorded

Mar 2026 — Present [monthly]

Active Not Recruiting PHASE3
Feb 2026 — Mar 2026 [monthly]

Active Not Recruiting PHASE3
Dec 2025 — Feb 2026 [monthly]

Active Not Recruiting PHASE3
Sep 2025 — Dec 2025 [monthly]

Active Not Recruiting PHASE3
Sep 2024 — Sep 2025 [monthly]

Active Not Recruiting PHASE3

▶ Show 14 earlier versions

Aug 2024 — Sep 2024 [monthly]

Active Not Recruiting PHASE3
Jul 2024 — Aug 2024 [monthly]

Active Not Recruiting PHASE3
Aug 2023 — Jul 2024 [monthly]

Active Not Recruiting PHASE3
Jan 2023 — Aug 2023 [monthly]

Active Not Recruiting PHASE3
Nov 2022 — Jan 2023 [monthly]

Active Not Recruiting PHASE3

Status: Recruiting → Active Not Recruiting
Jan 2021 — Nov 2022 [monthly]

Recruiting PHASE3
Jun 2020 — Jan 2021 [monthly]

Recruiting PHASE3
Feb 2020 — Jun 2020 [monthly]

Recruiting PHASE3
Nov 2018 — Feb 2020 [monthly]

Recruiting PHASE3
Jun 2018 — Nov 2018 [monthly]

Recruiting PHASE3
Dec 2017 — Jun 2018 [monthly]

Recruiting PHASE3
Oct 2017 — Dec 2017 [monthly]

Recruiting PHASE3
Feb 2017 — Oct 2017 [monthly]

Recruiting PHASE3
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE3

First recorded

Oct 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Data source: Eastern Cooperative Oncology Group

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aberdeen, United States , Abington, United States , Adrian, United States , Akron, United States , Albany, United States , Albuquerque, United States , Alexandria, United States , Allentown, United States , Amarillo, United States , American Fork, United States and 588 more locations